Leerink Swann started coverage on shares of Axovant Gene Therapies (NASDAQ:AXGT) in a report issued on Friday, June 21st, Marketbeat reports. The firm set an “outperform” rating and a $5.79 price target on the stock. Leerink Swann’s target price points to a potential downside of 21.54% from the company’s previous close.
Several other brokerages also recently issued reports on AXGT. ValuEngine downgraded shares of USD Partners from a “hold” rating to a “sell” rating in a research note on Friday, June 14th. Chardan Capital upgraded shares of Axovant Gene Therapies from a “neutral” rating to a “buy” rating and set a $32.00 target price for the company in a research note on Monday, March 11th. HC Wainwright reissued a “buy” rating and issued a $25.00 price target on shares of Kadmon in a report on Tuesday, March 12th. JMP Securities increased their price target on shares of Axovant Gene Therapies from $8.00 to $28.00 and gave the company an “outperform” rating in a report on Thursday, June 6th. Finally, Evercore ISI began coverage on shares of Homology Medicines in a report on Thursday, April 11th. They issued an “outperform” rating and a $29.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Axovant Gene Therapies currently has a consensus rating of “Buy” and a consensus target price of $28.76.
NASDAQ:AXGT traded up $0.05 during mid-day trading on Friday, hitting $7.38. The stock had a trading volume of 815,535 shares, compared to its average volume of 1,353,143. Axovant Gene Therapies has a twelve month low of $3.81 and a twelve month high of $21.92. The firm has a market cap of $168.12 million, a PE ratio of -0.92 and a beta of 1.28. The stock has a 50 day simple moving average of $6.16. The company has a debt-to-equity ratio of 0.41, a quick ratio of 2.63 and a current ratio of 2.63.
In related news, CEO Pavan Cheruvu purchased 7,500 shares of the stock in a transaction on Friday, June 14th. The shares were purchased at an average cost of $5.21 per share, with a total value of $39,075.00. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. 3.20% of the stock is owned by corporate insiders.
Institutional investors have recently added to or reduced their stakes in the business. Marshall Wace LLP bought a new position in Axovant Gene Therapies in the 1st quarter valued at about $272,000. Primecap Management Co. CA bought a new position in Axovant Gene Therapies in the 1st quarter valued at about $1,400,000. Finally, Sphera Funds Management LTD. bought a new position in shares of Axovant Gene Therapies during the first quarter worth approximately $6,794,000.
Axovant Gene Therapies Company Profile
Axovant Gene Therapies Ltd., a clinical-stage gene therapy company, focuses on developing a pipeline of product candidates for debilitating neurological and neuromuscular diseases. The company's current pipeline of gene therapy candidates targets GM1 gangliosidosis, GM2 gangliosidosis, Parkinson's disease, oculopharyngeal muscular dystrophy, amyotrophic lateral sclerosis, and frontotemporal dementia.
Featured Article: The limitations of an equal weight rating
Receive News & Ratings for Axovant Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.